On November 27, 2023, GSK announced positive results from the DREAMM-7 phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma. The trial demonstrated a significant improvement in progression-free survival (PFS) when belantamab mafodotin was combined with bortezomib and dexamethasone (BorDex) compared to the standard of care, daratumumab plus BorDex. Additionally, there was a strong trend towards improved overall survival (OS). The trial will continue to monitor OS outcomes.

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, expressed optimism about the potential of belantamab mafodotin combined with BorDex to address the unmet needs of relapsed/refractory multiple myeloma patients.

The safety and tolerability of the belantamab mafodotin regimen were consistent with the known profiles of the individual agents. The detailed results from the interim analysis will be presented at a future scientific meeting and shared with health authorities.

The DREAMM clinical development program will further explore the potential of belantamab mafodotin in early lines of treatment and in combination with other therapies. The ongoing DREAMM-8 trial will evaluate belantamab mafodotin in combination with pomalidomide and dexamethasone versus bortezomib in combination with pomalidomide and dexamethasone, with data expected in the second half of 2024. Read the full press release to learn more.